the Company has financed its operations and technology acquisitions primarily through equity financing, proceeds from the exercise of warrants and stock options, advances made by Hanmi (as defined be…
We have licensed important portions of our intellectual property from Hanmi, and are subject to significant obligations under those license agreements.
pursuant to a plan of arrangement of the Company under the Canada Business Corporations Act (the "Arrangement") whereby Hanmi Purchaser will acquire all of the issued and outstanding Common Shares of…
On February 7, 2025, the Company and Keystone Capital Partners, LLC ("Keystone") entered into a purchase agreement (the "Purchase Agreement"), which provides that subject to the terms and conditions …
the Purchaser, a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd., will acquire all of the issued and outstanding common shares of the Corporation
the Purchaser, a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd., will acquire all of the issued and outstanding common shares of the Corporation
Aptose Biosciences Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
APTOF-DEBT-7807
Warrants outstanding: 0.001
90%
xbrl warrant detail from xbrl 2025-12-31.
APTOF-DEBT
Debt stack $33.0M
90%
Market cache reports total debt of $33.0M.
APTOF-DEBT-7808
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2026-03-31.
Aptose Biosciences Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Aptose Biosciences Inc..
Aptose Biosciences Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Aptose Biosciences Inc..
Aptose Biosciences Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
